Approved for the treatment of Schizophrenia and
for the maintenance treatment of
Bipolar I Disorder
RISPERDAL CONSTA® Has a Demonstrated* Safety and Tolerability Profile
*Demonstrated in 2 long-term, randomized, double-blind, placebo-controlled clinical trials.1
Monotherapy Trial
As observed in the monotherapy clinical trial, the most common adverse reaction in patients with bipolar disorder was weight increase (5%).1 Discontinuation rates due to adverse reactions for RISPERDAL CONSTA® were 0.6% (vs 0% with placebo).1
Adverse Reactions From the Monotherapy Trial
(≥2% of patients)1